Dalton and colleagues [33] previously showed that bortezomib decreases FA/BRCA gene expression in multiple myeloma cells, and that NF-κB transcriptionally upregulates the FA/BRCA pathway. The gene discussed is NFKB1; the disease is AL amyloidosis.